Congenital Adrenal Hyperplasia clinical trials at University of California Health
3 in progress, 2 open to eligible people
Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
open to eligible people ages 1-17
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).
at UCSF
Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
open to eligible people ages 3 months to 47 months
The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to <4 years of age with CAH.
at UCSF
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Sorry, in progress, not accepting new patients
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind, placebo-controlled period, followed by 1 year of active treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 20 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).
at UCSF
Last updated: